RedHill Biopharma | RDHL - Cost Of Sales

Redhill Biopharma reported $9.45M in Cost of Sales for its third fiscal quarter of 2022.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

API Features Documentation Interested? Click here to contact us
Please Paste this Code in your Website
width
height
 Preview
Cost Of Sales Change
Adamis Pharmaceuticals ADMP:US USD 2.48M 834.2K
Cara Therapeutics CARA:US USD 2.13M 925K
Cronos Group Inc CRON:CN USD 23.12M 3.36M
Intra Cellular Therapies ITCI:US USD 6.79M 938K